NAD+ Falls 50% by Age 60: The Sirtuin
Science Behind Cellular Aging
NAD+ is the obligate coenzyme for over 500 enzymatic reactions — and the exclusive fuel source for the sirtuin enzymes that maintain your epigenome. By age 60, most people have lost roughly half of it. Here's the mechanism behind the decline, and what the actual human trial data says about NMN and NR precursor research.
閱讀中文版 →Not a Single-Function Molecule: Why NAD+ Decline Hits Everything at Once
Peer-reviewed mechanismNAD+ (nicotinamide adenine dinucleotide) is not one thing — it is a biochemical hub. Its redox cycling underpins cellular energy metabolism, while its consumption as a substrate drives DNA repair, gene silencing, and circadian rhythm maintenance. This duality is what makes its age-related decline so consequential: a falling NAD+ pool doesn't slow one process, it simultaneously degrades every system that depends on it.
Tissue survey data: Landmark surveys — including the Verdin laboratory's analysis of human skeletal muscle, liver, brain, and skin biopsies — documented approximately a 50% reduction in NAD+ concentration between the third and sixth decade of life. Skeletal muscle is particularly affected given its high mitochondrial density and oxidative NAD+ demand.
The Depletion Cascade: How Three Enzymes Compete for a Shrinking Pool
Peer-reviewed mechanismThe decline isn't a single broken switch — it's three competing consumption pathways that amplify one another in a self-reinforcing cycle.
Genetic evidence for the CD38 axis: Camacho-Pereira et al. (Cell Metabolism, 2016) showed that CD38 knockout mice — which maintain elevated NAD+ with aging — preserve SIRT3 activity, show reduced mitochondrial protein acetylation, and display significantly attenuated age-associated metabolic decline. This directly implicates the CD38 → NAD+↓ → SIRT3↓ → mitochondrial dysfunction axis as a tractable research target.
Sirtuins: The Enzymes That Run Out of Fuel
Peer-reviewed mechanismThe Michaelis constant (Km) for NAD+ in SIRT1 is roughly 94–880 µM depending on substrate; SIRT3's Km is around 880 µM. Measured NAD+ in aged human muscle falls to the 300–500 µM range — approaching or falling below these thresholds. In practical terms: at aged-tissue NAD+ concentrations, sirtuins simply can't run at full speed, regardless of how much sirtuin protein is present.
NMN vs. NR vs. IV: Comparing the Precursor Research
Peer-reviewed mechanismNAD+ itself doesn't readily cross cell membranes, so research has focused on precursors that feed the salvage pathway through different entry points.
| Metric | NMN (oral) | NR (oral) | NAD+ IV infusion |
|---|---|---|---|
| Salvage entry | NMNAT1–3 (direct NMN→NAD+) | NRK1/2 (NR→NMN→NAD+) | Direct, bypasses GI tract |
| Human evidence | Yoshino M et al., Science 2021 — muscle biopsy-confirmed NAD+ rise | Trammell et al., Nat Commun 2016 — first confirmed oral bioavailability | Clinical case series; no large RCT to date |
| Key animal data | Mills KF et al., Cell Metab 2016 — 12-month aged-mouse study | Cantó C et al., Cell Metab 2012 — SIRT1/3 activation, metabolic protection | Rapid tissue saturation; limited by route practicality |
| Stability | Stable lyophilized; NAD+ in solution degrades fast (~7-day window, 2–8°C) | Stable solid; hygroscopic, store desiccated | Prepared fresh; minimal solution shelf-life |
The Yoshino 2021 Human Trial
The most-cited human NMN trial gave postmenopausal women with prediabetes 250 mg/day oral NMN for 10 weeks in a randomized, placebo-controlled crossover design. Skeletal muscle biopsy metabolomics confirmed tissue-level NAD+ elevation — not just a blood marker — and insulin-stimulated glucose disposal improved significantly. This was the first human trial to confirm oral NMN actually reaches muscle tissue and elevates local NAD+ metabolites.
The Mills 2016 Aged-Mouse Study
Aged mice (18–24 months) given NMN in drinking water for 12 months showed attenuation across multiple aging markers simultaneously: energy metabolism, muscle mass and function, eye function, bone density, lipid profile, and immune function — consistent with NAD+'s role as a systemic hub rather than a single-pathway target.
Stability note: NAD+ undergoes rapid non-enzymatic hydrolysis in solution, especially above 4°C. Reconstituted NAD+ has a functional research window of roughly 7 days at 2–8°C; repeated freeze-thaw accelerates degradation. Lyophilized NMN/NR powders are substantially more stable and are generally preferred where consistent potency across a multi-day timeline matters. Full protocol in our Reconstitution Guide.